News About: Pharm. Industry
Ilyang generous with dividends
Ilyang Pharmaceutical was the most generous in offering dividend rewards among the 55 local pharmaceutical firms in 2010, according to Yakup. com., an information provider.
Ilyang topped the list by paying out 70 p...
Dual punishment perplexes drug companies’ salespeople
Last November the Ministry of Health and Welfare launched a crackdown on unlawful drug marketing activities. It introduced a rule which slashes the price of a drug by up to 20 percent if its producer is found to have ...
Dong-A, GSK gear up cooperation in healthcare sector
Dong-A Pharmaceutical said it will co-market GlaxoSmithKline (GSK)’s Polident and Sendodyne from June, while GSK will co-promote Dong-A’s Garglin in department stores.
Analysts are expecting Dong-A’s partnership wi...
Seven drugmakers to face price cut measures
A total of seven pharmaceutical firms, who were found to provide illegal rebate or kickbacks, will be subject to disciplinary action.
The Health Insurance Review Assessment and Service said Thursday that the author...
Takeda Korea’s sales policy ignites controversy
Local wholesalers are furious at CJ CheilJedang’s attitude as the latter did not inform them of any notice over Takeda Korea’s sales policy.
Wholesalers claimed that CJ failed to inform them of any notice on the ch...
KFDA chief likely to be replaced in May
Speculation has been growing that President Lee Myung-bak may replace some vice ministers within this month at the latest.
Sources say the Korea Food and Drug Administration Chief Noh Yun-hong is expected to be rep...
KFDA approves Nycomed’s oral COPD therapy
Nycomed Korea has announced that Daxas (roflumilast) was approved by the Korea Food and Drug Administration as an oral treatment to reduce the risk of chronic obstructive pulmonary disease (COPD) exacerbations in pati...
Kanarb likely to be prescribed in 40 general hospitals in second half
Boryung Pharmaceutical is enjoying brisk sales of its new antihypertensive drug, Kanarb (fimasartan).
Monthly sales of Kanarb is expected to reach 1,000 million won in the first half of this year, as it has succeed...
Wholesalers to face thinner margin
As Japanese drugmakers in Korea are poised to reduce wholesaler margin, hundreds of local wholesalers went up in arms against the new movement, seeing it as a threat to their business.
They established an emergenc...
Baraclude and Viread to drive market growth in Korea
The domestic hepatitis B market is expected to witness significant changes as Yuhan’s Viread (tenofovir) is to be launched in the latter half of this year.
Currently, BMS’s Varaclude (entecavir) has led the domesti...
